J A Carrillo, J Benítez. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » AdultAntineoplastic Agents/pharmacologyAntineoplastic Agents/therapeutic useAntipsychotic Agents/pharmacologyAntipsychotic Agents/therapeutic useBenzodiazepinesCaffeine/urineCarcinogens/metabolismChemopreventionCytochrome P-450 CYP1A1/antagonists & inhibitorsCytochrome P-450 CYP1A1/metabolismCytochrome P-450 CYP1A2/metabolismCytochrome P-450 CYP1A2 InhibitorsCytochrome P-450 CYP2D6/metabolismCytochrome P-450 CYP2D6 InhibitorsEnzyme Inhibitors/pharmacologyEnzyme Inhibitors/therapeutic useFemaleHumansMaleMiddle AgedNeoplasms/enzymologyNeoplasms/prevention & controlOlanzapinePirenzepine/analogs & derivativesPirenzepine/pharmacologyPirenzepine/therapeutic use
Substances: See more » Antineoplastic AgentsAntipsychotic AgentsCarcinogensCytochrome P-450 CYP1A2 InhibitorsCytochrome P-450 CYP2D6 InhibitorsEnzyme InhibitorsBenzodiazepinesPirenzepineCaffeineCytochrome P-450 CYP1A1Cytochrome P-450 CYP1A2Cytochrome P-450 CYP2D6Olanzapine
Year: 1999 PMID: 10492064 DOI: 10.1007/s002280050661
Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN: 0031-6970 Impact factor: 2.953